Number of outstanding shares in Elekta AB (publ)
The increase of 39 new B shares is attributable to the conversion of shares within the framework of the 2012/17 convertible bond.
One A share entitles the holder to ten votes and one B share to one vote.
# # #
For further information, please contact:
Johan Andersson, Director Investor Relations, Elekta AB
Tel: +46 702 100 451, email: email@example.com
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 18:00 CET on July 31, 2013.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com